Allianz Asset Management GmbH Invests $203,000 in Urogen Pharma $URGN

Allianz Asset Management GmbH purchased a new position in shares of Urogen Pharma (NASDAQ:URGN) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 14,800 shares of the company’s stock, valued at approximately $203,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Urogen Pharma by 216.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,360,524 shares of the company’s stock valued at $48,227,000 after buying an additional 2,983,368 shares during the period. RA Capital Management L.P. bought a new stake in Urogen Pharma in the first quarter valued at $35,461,000. Vestal Point Capital LP increased its stake in Urogen Pharma by 32.1% in the first quarter. Vestal Point Capital LP now owns 2,152,957 shares of the company’s stock valued at $23,812,000 after purchasing an additional 522,957 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its position in shares of Urogen Pharma by 14.6% during the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 786,472 shares of the company’s stock worth $8,698,000 after acquiring an additional 100,000 shares in the last quarter. Finally, Parkman Healthcare Partners LLC increased its position in shares of Urogen Pharma by 6.3% during the first quarter. Parkman Healthcare Partners LLC now owns 393,153 shares of the company’s stock worth $4,348,000 after acquiring an additional 23,292 shares in the last quarter. Institutional investors and hedge funds own 91.29% of the company’s stock.

Insider Transactions at Urogen Pharma

In other news, General Counsel Jason Drew Smith sold 1,520 shares of the stock in a transaction on Monday, September 8th. The shares were sold at an average price of $19.11, for a total value of $29,047.20. Following the transaction, the general counsel owned 43,305 shares of the company’s stock, valued at $827,558.55. This represents a 3.39% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Mark Schoenberg sold 10,000 shares of the stock in a transaction on Monday, August 11th. The stock was sold at an average price of $17.69, for a total transaction of $176,900.00. Following the completion of the transaction, the insider directly owned 148,229 shares in the company, valued at $2,622,171.01. The trade was a 6.32% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 14,594 shares of company stock valued at $259,713 in the last quarter. Insiders own 4.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on URGN. Piper Sandler began coverage on shares of Urogen Pharma in a research report on Monday, August 18th. They set an “overweight” rating and a $36.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a research report on Wednesday, October 8th. HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of Urogen Pharma in a research report on Monday. D. Boral Capital restated a “buy” rating and set a $25.00 price target on shares of Urogen Pharma in a report on Monday. Finally, Wall Street Zen cut shares of Urogen Pharma from a “hold” rating to a “sell” rating in a report on Saturday, October 18th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Urogen Pharma has a consensus rating of “Moderate Buy” and an average price target of $32.00.

Urogen Pharma Trading Down 3.2%

Urogen Pharma stock opened at $20.18 on Wednesday. The firm’s 50 day simple moving average is $18.44 and its 200 day simple moving average is $14.52. The firm has a market capitalization of $933.53 million, a PE ratio of -6.08 and a beta of 1.00. Urogen Pharma has a 1-year low of $3.42 and a 1-year high of $21.71.

Urogen Pharma (NASDAQ:URGN) last posted its earnings results on Thursday, August 7th. The company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.23). The firm had revenue of $24.22 million for the quarter, compared to the consensus estimate of $23.06 million. Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 164.44%. Research analysts forecast that Urogen Pharma will post -3.12 earnings per share for the current year.

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.